https://orcid.org/0000-0003-4991-9790
References
- Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2008;179(5 Suppl):S75–80.
- Chong C, Fong L, Lai R, et al. The prevalence of lower urinary tract symptoms and treatment-seeking behaviour in males over 40 years in Singapore: a community-based study. Prostate Cancer Prostatic Dis. 2012;15(3):273–277.
- Fourcade R-O, Lacoin F, Rouprêt M, et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol. 2012;30(3):419–426.
- Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the combat study. Eur Urol. 2010;57:123–131. ••The CombAT trial provides the basis for transition probabilities of the medication arm.
- Zang YC, Deng XX, Yang DR, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis of randomized controlled trials. Lasers Med Sci. 2016;31:235–240.
- Flanigan R, Reda D, Wasson JH, et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a department of veterans affairs cooperative study. J Urol. 1998;160:12–17.
- Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24:8802–8813.
- Dbc W, Yee CH, Ng CF, et al. Economic evaluation of combination therapy versus monotherapy for treatment of benign prostatic hyperplasia in Hong Kong. Front Pharmacol. 2018;9:1078.
- Erman A, Masucci L, Krahn MD, et al. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis. BJU Int. 2018;122:879–888.
- Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clin Outcomes Res. 2018;10:29–43.
- Ray A, Morgan H, Wilkes A, et al. The urolift system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a NICE medical technology guidance. Appl Health Econ Health Policy. 2016;14:515–526.
- Agency for Care Effectiveness. Medical technologies evaluation methods and process guide. 2022.
- Rieken M, Bachmann A, Shariat SF. Long-term follow-up data more than 5 years after surgical management of benign prostate obstruction: who stands the test of time? Curr Opin Urol. 2016;26:22–27.
- Reich O, Gratzke C, Stief CG. Techniques and long-term results of surgical procedures for BPH. Eur Urol. 2006;49:970–978.
- Ministry of Health. Fee benchmarks and bills amount information [Internet]. 2019 [cited 2020 June 15]. Available from: https://www.moh.gov.sg/cost-financing/fee-benchmarks-and-bill-amount-information.
- Foo KT, Hss H, Wong MYC, et al. Singapore urological association clinical guidelines for male lower urinary tract symptoms/benign prostatic hyperplasia. Singapore Med J. 2017;58:473–480.
- Department of statistics Singapore. Death and life expectancy [Internet]. Dep. Stat. Singapore. 2017 [cited 2020 June 15]. Available from: https://www.singstat.gov.sg/find-data/search-by-theme/population/death-and-life-expectancy/latest-data.
- Baladi JF, Menon D, Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics. 1996;9:443–454.
- Hussein Al Awamlh B A, Lee R, Chughtai B, et al. A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration. Urology. 2015;85:381–387.
- Singapore General Hospital. Estimated Hospital Bills. 2020.
- Lum ZK, Suministrado MSP, Venketasubramanian N, et al. Medication compliance in Singaporean patients with Alzheimer’s disease. Singapore Med J. 2019;60:154–160.
- Lin L-K, Sun Y, Heng BH, et al. Medication adherence and glycemic control among newly diagnosed diabetes patients. BMJ Open Diabetes Res Care. 2017;5:e000429.
- Luo N, Wang P, Thumboo J, et al. Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states. Pharmacoeconomics. 2014;32:495–507.
- McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021;206:715–724.